April 26th 2024
The clinical manifestations of shingles can be divided into 3 phases.
Reducing Barriers Associated With Pneumococcal Vaccine Uptake
1.5 Credits / Immunization, Infectious Diseases
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Vaccine-Preventable Diseases: Strategies for Addressing Vaccine Hesitancy and Improving Vaccine Confidence
1.0 Credit / Immunization
View More
The Expanding Landscape of Vaccinations for the Prevention of Pneumococcal Disease: The Role of the Pharmacist as Patient Educator and Vaccinator
1.0 Credit / Pneumococcal Disease
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Influenza Prevention in the At-Risk Adult Population and the Pharmacist's Role in an Evolving Influenza Vaccine Landscape
1.25 Credits / Immunization, Infectious Disease
View More
Identifying Candidates for Meningococcal Vaccines (Pharmacy Technician Credit)
2.0 Credits / Immunization
View More
Identifying Candidates for Meningococcal Vaccines (Pharmacist Credit)
2.0 Credits / Immunization
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
The Pharmacist’s Impact on Shingles Prevention Through Vaccination: Recommendations, Uptake, and Improved Outcomes
1.5 Credits / Immunization
View More
How Will the Extinction of B/Yamagata Impact Global Flu Vaccination Strategies?
February 13th 2024Drug Topics talked with Gregg Sylvester, MD, chief health officer and vice president of medical affairs at CSL Seqirus, about what we can learn from this unique situation to improve future vaccine development and distribution.
Cell-Based Flu Vaccine May Be More Cost-Effective, Beneficial Among Children
January 30th 2024A new study found that switching from a primary national plan of egg-based vaccines to cell-based vaccines for the flu would significantly reduce the impact of the seasonal virus at a lesser production and distribution cost.
Moderna’s mRNA RSV Vaccine Shows Positive Results in Phase 3 Trial
January 3rd 2024The vaccine, called mRNA-1345, demonstrated an efficacy of 83.7% against RSV-associated lower respiratory tract disease with at least 2 signs or symptoms and 82.4% against the disease with at least 3 signs or symptoms.
Sanofi, AstraZeneca Will Release Additional Doses of Nirsevimab-Alip to Meet Unprecendented Demand
December 19th 2023In January 2024, Sanofi and AstraZenenca will release 230,000 additional doses of nirsevimab-alip, heeding guidance from the CDC to leverage all tools to increase immunizations against RSV.